| First Author | Ciecko AE | Year | 2019 |
| Journal | Cell Rep | Volume | 29 |
| Issue | 10 | Pages | 3073-3086.e5 |
| PubMed ID | 31801074 | Mgi Jnum | J:285456 |
| Mgi Id | MGI:6393036 | Doi | 10.1016/j.celrep.2019.11.010 |
| Citation | Ciecko AE, et al. (2019) Interleukin-27 Is Essential for Type 1 Diabetes Development and Sjogren Syndrome-like Inflammation. Cell Rep 29(10):3073-3086.e5 |
| abstractText | Human genetic studies implicate interleukin-27 (IL-27) in the pathogenesis of type 1 diabetes (T1D), but the underlying mechanisms remain largely unexplored. To further define the role of IL-27 in T1D, we generated non-obese diabetic (NOD) mice deficient in IL-27 or IL-27Ralpha. In contrast to wild-type NOD mice, both NOD.Il27(-/-) and NOD.Il27ra(-/-) strains are completely resistant to T1D. IL-27 from myeloid cells and IL-27 signaling in T cells are critical for T1D development. IL-27 directly alters the balance of regulatory T cells (Tregs) and T helper 1 (Th1) cells in pancreatic islets, which in turn modulates the diabetogenic activity of CD8 T cells. IL-27 also directly enhances the effector function of CD8 T cells within pancreatic islets. In addition to T1D, IL-27 signaling in T cells is also required for lacrimal and salivary gland inflammation in NOD mice. Our study reveals that IL-27 contributes to autoimmunity in NOD mice through multiple mechanisms and provides substantial evidence to support its pathogenic role in human T1D. |
